Two scientists will lead a third-party consumer research study on the effects of regular CBD use on humans, particularly focused on liver safety.

Dr. Keith Aqua, a Miami-based medical doctor, and Dr. Jeff Lombardo, a Buffalo, New York-based pharmacist who specializes in toxicology, are the co-principal investigators for a national clinical trial measuring the potential liver effects in healthy adults who are ingesting hemp-derived CBD.

The research will look at the effects of full- and broad-spectrum CBD as well as CBD isolate.

The study, which has been approved by the Institutional Review Board, an organization that provides oversight for human clinical studies, was developed by ValidCare, a Colorado firm that conducts clinical and market-intelligence research for the hemp and health care industries. ValidCare received significant feedback on the scope of the study from the agency’s CBD Working Group.

More at

Scientists explain how liver study will provide FDA with ‘real world’ data on CBD